Association between  BRCA1  P871L polymorphism and cancer risk: evidence from a meta-analysis

Limin Miao; Yang Yu; Yefeng Ji; Bo Zhang; Zhiyao Yuan; Yifei Du; Longbiao Zhu; Ruixia Wang; Ning Chen; Hua Yuan

doi:10.18632/oncotarget.15739

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Association between BRCA1 P871L polymorphism and cancer risk: evidence from a meta-analysis

Limin Miao, Yang Yu, Yefeng Ji, Bo Zhang, Zhiyao Yuan, Yifei Du, Longbiao Zhu, Ruixia Wang, Ning Chen and Hua Yuan _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:30587-30594. https://doi.org/10.18632/oncotarget.15739

Metrics: PDF 2063 views | HTML 2196 views | ?

Abstract

Limin Miao1,*, Yang Yu1,*, Yefeng Ji1, Bo Zhang1, Zhiyao Yuan1, Yifei Du1, Longbiao Zhu1, Ruixia Wang1, Ning Chen1,2 and Hua Yuan1,2

1 Jiangsu Key Laboratory of Oral Diseases, Nanjing Medical University, Nanjing, China

2 Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, China

* These authors have contributed equally to this work

Correspondence to:

Hua Yuan, email:

Keywords: BRCA1, polymorphism, cancer risk, meta-analysis

Received: November 09, 2016 Accepted: February 13, 2017 Published: February 25, 2017

Abstract

Breast cancer 1 (BRCA1) gene makes great contributions to the repair of DNA. The association between BRCA1 P871L polymorphism and cancer risk has been investigated in a growing number of studies, but the conclusions are not conclusive. To obtain a comprehensive conclusion, we performed a meta-analysis of 24 studies with 13762 cases and 22388 controls. The pooled results indicated that BRCA1 gene P871L variant decreased risk of overall cancer (homozygous model: odds ratio (OR) = 0.89, 95%confidence interval (CI) = 0.79-1.00; recessive model: OR = 0.89, 95% CI = 0.80-0.99). The stratified analysis observed decreased risk associated with BRCA1 P871L in subgroups among Asians and high score studies, but not Caucasians or low score studies. In conclusion, despite several limitations, this meta-analysis suggested that BRCA1 P871L genetic variation may be associated with decreased susceptibility to cancer.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15739

Publication Alerts

Post-Publication Promotion

Publication Discount

Reviews:

Association between BRCA1 P871L polymorphism and cancer risk: evidence from a meta-analysis

Abstract